Key Points:
1) Firdapse for the Treatment of LEMS with a Breakthrough Therapy Designation From FDA
2) CPP-115 in pipeline for the treatment of infantile spasms
3) CPP-115 in pipeline for the treatment of complex partial seizures
4) CPP-115 in pipeline for the treatment of Dyskinesia in Parkinson's
5) CPP-109 in pipeline for the treatment of Tourett's disorder
6) BioMarin's investment
7) Mr. Silverman, inventor of Pfizer's Lyrica, on the advisory board for CPRX
8) 35% of shares held by insiders
9) 15% short and growing
10) low float, only 28 million shares available for trading